Efficacy and safety of anlotinib as a third‑line treatment of advanced non‑small cell lung cancer: A meta‑analysis of randomized controlled trials

Zha,Bowen; Zhang,Yuxin; Yang,Runzi; Kamili,Muladili

doi:10.3892/ol.2022.13350

Efficacy and safety of anlotinib as a third‑line treatment of advanced non‑small cell lung cancer: A meta‑analysis of randomized controlled trials

Authors:
- Bowen Zha
- Yuxin Zhang
- Runzi Yang
- Muladili Kamili
View Affiliations

Affiliations: Department of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China, Department of Evidence‑Based Medicine, School of Public Health, Capital Medical University, Beijing 100069, P.R. China, Department of Education, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: May 27, 2022 https://doi.org/10.3892/ol.2022.13350
Article Number: 229
Copyright: © Zha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit both tumor angiogenesis and signal transduction pathways associated with proliferation. The main proposed mechanism of anlotinib inhibiting tumor angiogenesis is that anlotinib inhibits the activation of VEGFR2, PDGFRβ and FGFR1, and downstream ERK signal transduction. The aim of the present study was to systematically evaluate the efficacy and safety of third‑line treatment with anlotinib for advanced non‑small cell lung cancer (NSCLC). To meet this aim, studies published up to February 2022 were searched in PubMed, Web of Science, the Cochrane Library and several Chinese databases. Only randomized controlled trials (RCTs) were included and a metaanalysis was performed using RevMan 5.3 software. A total of 18 RCTs were identified and included in the present study, comprising 1,658 patients. The anlotinib treatment group was indicated to be better than the control group at prolonging progression‑free survival [hazard ratio (HR), 0.33; 95% confidence interval (95% CI), 0.28‑0.37] and overall survival (HR, 0.70; 95% CI, 0.60‑0.81). Anlotinib also provided a significant improvement in the disease control rate [risk ratio (RR), 1.51; 95% CI, 1.27‑1.79], objective response rate (1.75, 95% CI, 1.51‑2.03) and Karnofsky performance status (mean difference, 9.85; 95% CI, 6.26‑13.43). Compared with the control group, the incidence of adverse events (AEs), such as hypertension and hemoptysis, was increased by anlotinib. Through subgroup analysis, it was determined that, compared with the placebo, the incidence of AEs was increased by anlotinib, although compared with other therapeutic drugs, no significant differences were observed. In conclusion, the findings of the present study suggested that the thirdline treatment of advanced NSCLC with anlotinib is more effective compared with other control measures and that the AEs are also controllable. However, given the limitations of the quantity and the quality of the included studies, further studies are required to gain a more complete understanding of the effects of anlotinib.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Morgensztern D and Boshoff C: The biology and management of nonsmall cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Aokage K, Yoshida J, Hishida T, Tsuboi M, Saji H, Okada M, Suzuki K, Watanabe S and Asamura H: Limited resection for early-stage non-small cell lung cancer as function-preserving radical surgery: A review. Jpn J Clin Oncol. 47:7–11. 2017. View Article : Google Scholar : PubMed/NCBI
5	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, Screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
6	Broderick SR: Adjuvant and Neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 30:215–220. 2020. View Article : Google Scholar : PubMed/NCBI
7	Ruiz-Cordero R and Devine WP: Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 13:17–33. 2020. View Article : Google Scholar : PubMed/NCBI
8	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
10	Liang W, Zhong R and He J: Osimertinib in EGFR-mutated lung cancer. N Engl J Med. 384:6752021. View Article : Google Scholar : PubMed/NCBI
11	Belani CP and Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 46 (Suppl 2):S3–S11. 2004. View Article : Google Scholar : PubMed/NCBI
12	Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, et al: Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer. 131:27–36. 2020. View Article : Google Scholar : PubMed/NCBI
13	Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R and Zhao J: Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 11:1202018. View Article : Google Scholar : PubMed/NCBI
14	Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 Randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018. View Article : Google Scholar : PubMed/NCBI
15	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
16	Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al: The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
17	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
18	Borenstein M, Hedges LV, Higgins JP and Rothstein HR: A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 1:97–111. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen B, Sun J, Cai W and Chen J: Efficacy of anlotinib as a third-line therapy for non-small cell lung cancer. Chin J Clin Oncol Rehabil. 28:558–560. 2021.
20	Dai X, Wang Y, Han L, Liu Y and Li R: Clinical emcacy of AIllotinib in the treatment of advanced non-small cell lung cancer. Chin Med Herald. 16:95–98. 2019.
21	Feng Y, Yao F, Wang W, Guo J and Zhu Z: Short-term curative effect of anlotinib on non-small cell lung cancer and its influences on CTC and VGEF levels in peripheral blood and quality of life. J Clin Exp Med. 19:2399–2403. 2020.
22	Gou F, Yu D, Qiao Q and Zhou X: Clinical observation of anlotinib in the treatment of advanced lung adenocarcinoma with targeted therapy. Anti-Tumor Pharm. 10:343–348. 2020.
23	Han B, Kan N and Wang S: Explore the clinical efficacy and short-term prognosis of Anlotinib in the third-line treatment of advanced non-small cell lung cancer (NSCLC). Health Guide. 89–90. 2021.(In Chinese).
24	Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, et al: Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 118:654–661. 2018. View Article : Google Scholar : PubMed/NCBI
25	Huang P, Li W and Zhang H: Effect of anlotinib capsule on the level of VEGF and survival period in advanced non-small cell lung cancer. J Pract Cancer. 35:360–362. 2020.
26	Kong Q: Clinical effect of antinib in the thirdline treatment of nonsmall cell lung cancer and its clinical significance security analysis. Chin J Mod Drug Appl. 14:164–166. 2020.
27	Liu Q, Li J, Wang K and Zhang Y: Clinical efficacy of antinib in the treatment of patients with advanced lung cancer after operation. Mod Diagn Treat. 31:2602–2604. 2020.
28	Luo K and Yu H: Clinical observation on the treatment of advanced non-small cell lung cancer with Anrotinib III. Healthmust-Readmagazine. 7:452021.(In Chinese).
29	Si XY, Wang HP, Zhang XT, Wang MZ and Zhang L: Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer. Zhonghua Nei Ke Za Zhi. 57:830–834. 2018.(In Chinese). PubMed/NCBI
30	Sun X: Clinical efficacy and safety analysis of third-line treatment with enrotinib for advanced non-small cell lung cancer. Oriental Med Diet. 28:1172021.
31	Tian T, He M, Wu F, Lu Y and Liu Y: Short-term efficacy of anlotinib in the treatment of non-small cell lung cancer and its influence on serum tumor markers CTC VGEF and side effects. J Hebei Nat Sci. 27:1908–1912. 2021.
32	Wang C: The efficacy of Anlotinib capsule in the treatment of advanced non-small cell lung cancer. Chin Heal Standard Management. 11:75762020.(In Chinese).
33	Yang Y: The Efficacy of Anlotinib as a thirdor furtherline treatment in Patients with Advanced NSCLC. Master's Thesis. Zhengzhou University; 2018, (In Chinese).
34	Yu C and Liu L: Observation on the effect of third-line Anrotinib on advanced non-small cell lung cancer. Medical Innovation of China. 18:69–72. 2021.(In Chinese).
35	Zhu Y: Short-term efficacy and life of anlotinib thirdline and above in the treatment of advanced nonsmall cell lung cancer. Healthmust-Readmagazine. 24:982021.(In Chinese).
36	Nagano T, Tachihara M and Nishimura Y: Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Current Cancer Drug Targets. 19:595–630. 2019. View Article : Google Scholar : PubMed/NCBI
37	Zhao T, Wang X, Xu T, Xu X and Liu Z: Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 8:51492–51506. 2017. View Article : Google Scholar : PubMed/NCBI
38	Syed YY: Anlotinib: First global approval. Drugs. 78:1057–1062. 2018. View Article : Google Scholar : PubMed/NCBI
39	Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y and Lou L: Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109:1207–1219. 2018. View Article : Google Scholar : PubMed/NCBI
40	He C, Wu T and Hao Y: Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun. 503:3093–3099. 2018. View Article : Google Scholar : PubMed/NCBI
41	Yu G, Shen Y, Xu X and Zhong F: Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One. 15:e02429822020. View Article : Google Scholar : PubMed/NCBI
42	Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P and Amir E: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 53:120–127. 2017. View Article : Google Scholar : PubMed/NCBI
43	Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, et al: Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: A multicenter study. Oncology. 93 (Suppl 1):S113–S119. 2017. View Article : Google Scholar